meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID-19

results overview
latest studies
standard queries
browse treatments
mapping
NMA
methods

COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention

see more...

click on circles to display study description...

EPIC-SR, 0 NCT05011513

nirmatrelvir / ritonavir (Paxlovid) (n=1140) vs. placebo (n=-9)

randomized controlled trial risk of bias NA

Studied treatment

paxlovid

Control treatment

placebo

Patients

COVID 19 all comers

Method

double blind

Remark

interim results from pfizer press release https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results

powered by vis.js Network